Mentions in press and media 15
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 9, 2026 | Insilico Medicine Releases Positive Profit Alert for the First Half of 2026 | CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive prof... |
| Apr 29, 2026 | Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study | Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE. The inhalati... |
| Mar 23, 2026 | Когда вычисления станут бесконечными: разбор интервью Илона Маска от 5.02.26 | Преамбула. Человек в очереди В 1937 году дальнобойщик Малком МакЛин простоял несколько часов на причале в Нью-Джерси — ждал, пока грузчики вручную перекладывают тысячи ящиков с его грузовика на борт корабля. Разгрузка шла медленно: каждая е... |
| Mar 23, 2026 | Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery | CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the launch of PandaClaw, a transformative new... |
| Feb 3, 2026 | Что смогут ИИ-агенты к 2030-му году | Привет! На связи команда Research & Insights Центра стратегии цифровых продуктов МТС. В прошлом году мы подготовили исследование мирового и российского рынка ИИ-агентов. Перед вами четвертая часть обзора этого исследования. В первой мы ... |
| Jun 10, 2025 | Insilico Medicine Launches Nach01 Foundation Model on AWS Marketplace to Help Accelerate Generative Chemistry Innovation | CAMBRIDGE, Mass., June 10, 2025 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced the recent release of its Nach01 foundation model on Amazon Web Ser... |
| Feb 20, 2025 | The Future of Antibody Therapy: A New Era of Collaboration and Innovation | In the fast-paced world of biopharmaceuticals, collaboration is the name of the game. Harbour BioMed and Insilico Medicine are leading the charge. Their recent partnership marks a significant leap in antibody discovery and development. This... |
| Feb 20, 2025 | Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of ... |
| Jan 7, 2025 | Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease | Two separate Phase I studies conducted in Australia and in China indicate that ISM5411 was generally safe and well tolerated in all dose groups, demonstrating a favorable PK profile in validating gut-restrictive properties. Supported by Ins... |
Show more
Reviews 0
FAQ about Pharma.AI
What has the press written about Pharma.AI?
Parsers VC has collected 15 articles mentioning Pharma.AI, among them “Insilico Medicine Releases Positive Profit Alert for the First Half of 2026” (Jul 9, 2026) and “Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study” (Apr 29, 2026).
Is Pharma.AI still active?
Yes, Pharma.AI is active; its latest activity on Parsers VC dates from Oct 20, 2026.